Lung Ultrasound for the Emergency Diagnosis of Pneumonia, Acute Heart Failure, and Exacerbations of Chronic Obstructive Pulmonary Disease/Asthma in Adults: A Systematic Review and Meta-analysis

Lung ultrasound can accelerate the diagnosis of life-threatening diseases in adults with respiratory symptoms.
Source: The Journal of Emergency Medicine - Category: Emergency Medicine Authors: Tags: Ultrasound in Emergency Medicine Source Type: research

Related Links:

Abstract Dyspnea is a symptom arising from a complex interplay of diseases and physiologic states and is commonly encountered in primary care. It is considered chronic if present for more than one month. As a symptom, dyspnea is a predictor for all-cause mortality. The likeliest causes of dyspnea are disease states involving the cardiac or pulmonary systems such as asthma, chronic obstructive pulmonary disease, heart failure, pneumonia, and coronary artery disease. A detailed history and physical examination should begin the workup; results should drive testing. Approaching testing in stages beginning with first-l...
Source: American Family Physician - Category: Primary Care Authors: Tags: Am Fam Physician Source Type: research
Introduction: Patients with chronic obstructive pulmonary disease (COPD) have higher risk of hospitalization for cardiovascular events (CVE). An association between influenza infection and myocardial infarction (MI) is established. Our objective is to evaluate the COPD as an additional risk factor for CVE and respiratory events (RE) in patients with respiratory viral infection.Methods: We performed a retrospective cross-sectional analysis of 139 patients, with positive PCR for respiratory viruses in January of 2018. Cardiovascular risk factors (CVRF) (hypertension, diabetes, dyslipidemia and smoking) and medical history we...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Monitoring airway disease Source Type: research
What can we expect from the flu season this year? Unfortunately, many experts are predicting an active, and possibly severe, flu season. This projection is based on data from Australia, where the flu season is just wrapping up. Australia was hit early and hard by flu this year: over 300,000 patients had laboratory-confirmed influenza, a record number of cases. Flu outbreaks in the Southern Hemisphere happen during our summers, and they often give us a clue as to what we should expect when the flu lands on our shores in the fall. Who should get the flu vaccine? Basically, everybody over the age of 6 months, except for those...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Cold and Flu Health Prevention Vaccines Source Type: blogs
Publication date: May 2019Source: The Lancet Global Health, Volume 7, Issue 5Author(s): MyLinh Duong, Shofiqul Islam, Sumathy Rangarajan, Darryl Leong, Om Kurmi, Koon Teo, Kieran Killian, Gilles Dagenais, Scott Lear, Andreas Wielgosz, Sanjeev Nair, Viswanathan Mohan, Prem Mony, Rajeev Gupta, Rajesh Kumar, Omar Rahman, Khalid Yusoff, Johannes Lodewykus du Plessis, Ehimario U Igumbor, Jephat ChifambaSummaryBackgroundThe associations between the extent of forced expiratory volume in 1 s (FEV1) impairment and mortality, incident cardiovascular disease, and respiratory hospitalisations are unclear, and how these associations mi...
Source: The Lancet Global Health - Category: International Medicine & Public Health Source Type: research
Vapotherm said today that it launched its next-gen Precision Flow Hi-VNI system intended to relieve respiratory stress in spontaneously breathing patients. The Exeter, N.H.-based company touted that the next-gen device features improvements to both its software and hardware intended to improve reliability. The Precision Flow Hi-VNI system is designed to deliver maskless noninvasive ventilation to patients who are spontaneously breathing to relieve respiratory distress including hypercapnia, hypoxemia and dyspnea, Vapotherm said. The company’s Precision Flow devices are intended to provide high-velocity heated, humidi...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Respiratory Vapotherm Source Type: news
Conclusion: Rib raising was shown to be well tolerated by the majority of the patients in the study population. PMID: 30556829 [PubMed - as supplied by publisher]
Source: Journal of the American Osteopathic Association - Category: Complementary Medicine Tags: J Am Osteopath Assoc Source Type: research
Vapotherm said today it closed its initial public offering, raising a total $64.4 million in gross proceeds. The Exeter, N.H.-based company developed the Precision Flow line of devices to provide high-velocity heated, humidified and oxygenated air to treat patients with conditions such as pneumonia, chronic obstructive pulmonary disease, asthma and heart failure. Some 1,200 of the devices have been sold in the U.S., mostly into hospital ICUs, the company said. Vapotherm said it floated 4.6 million shares of its common stock at $14 per share, and that the offering featured a fully exercised underwriter’s option to pur...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Initial Public Offering (IPO) Respiratory Wall Street Beat Vapotherm Source Type: news
Vapotherm yesterday priced an initial public offering, aiming to raise $56 million for its respiratory device. Exeter, N.H.-based Vapotherm developed the Precision Flow line of devices to provide high-velocity heated, humidified and oxygenated air to treat patients with conditions such as pneumonia, chronic obstructive pulmonary disease, asthma and heart failure. Some 1,200 of the devices have been sold in the U.S., mostly into hospital ICUs, the company said. Vapotherm said it plans to issue 4 million shares at $14 apiece, hitting the low end of its prior range. The offering also includes a 30-day underwrit...
Source: Mass Device - Category: Medical Devices Authors: Tags: Featured Funding Roundup Initial Public Offering (IPO) Respiratory Wall Street Beat Vapotherm Source Type: news
Vapotherm today set the pricing range on an initial public offering that would fetch $60 million at the midpoint. Exeter, N.H.-based Vapotherm developed the Precision Flow line of devices to provide high-velocity heated, humidified and oxygenated air to treat patients with conditions such as pneumonia, chronic obstructive pulmonary disease, asthma and heart failure. Some 1,200 of the devices have been sold in the U.S., mostly into hospital ICUs, the company said. Today Vapotherm said it plans to issue 4 million shares priced at $14 to $16 apiece, for gross proceeds of $56.0 million to $64 million. Vapotherm has said t...
Source: Mass Device - Category: Medical Devices Authors: Tags: Featured Funding Roundup Initial Public Offering (IPO) Respiratory Wall Street Beat Source Type: news
Vapotherm last week registered for an initial public offering worth nearly $58 million for the respiratory device it’s developing. Exeter, N.H.-based Vapotherm developed the Precision Flow line of devices to provide high-velocity heated, humidified and oxygenated air to treat patients with conditions such as pneumonia, chronic obstructive pulmonary disease, asthma and heart failure. Some 1,200 of the devices have been sold in the U.S., mostly into hospital ICUs, the company said. In an Oct. 19 filing with the U.S. Securities &Exchange Commission, Vapotherm said the proceeds from the $57.5 million offering ar...
Source: Mass Device - Category: Medical Devices Authors: Tags: Featured Funding Roundup Respiratory Wall Street Beat Vapotherm Source Type: news
More News: Asthma | Cardiology | Chronic Obstructive Pulmonary | Emergency Medicine | Heart | Heart Failure | Pneumonia | Respiratory Medicine | Ultrasound